替吉奥联合阿帕替尼维持治疗Ⅲ期宫颈癌的临床效果

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (856 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Tegafur combined with Apatinib in the maintenance therapy of stage Ⅲcervical cancer.Methods The clinical data of 65 patients with cervical cancer admitted to Jiangmen Central Hospital from January 2016 to June 2017 were retrospectively analyzed.They were divided into control group (n=30) and maintenance chemotherapy group (n=35) according to different treatment methods.Both groups received the same regimens of chemoradiotherapy.After the end of chemoradiotherapy,the control group underwent regular reexamination,and the maintenance chemotherapy group received maintenance treatment of Tegafur combined with Apatinib.Treatment effect,quality of life score,progression-free survival and incidence of adverse reactions were compared between the two groups.Results The total effective rate of maintenance chemotherapy group was 71.43%,higher than 36.67% of control group,the difference was statistically significant (P<0.05).The quality of life score of the maintenance chemotherapy group was higher than that of the control group,the difference was statistically significant (P<0.05).Progression-free survival was (11.46±2.01) months in the maintenance chemotherapy group,longer than (9.35±1.24) months in the control group,the difference was statistically significant (P<0.05).There was no significant difference in the incidence of bone marrow suppression,edema,gastrointestinal reaction and hypertension between the two groups (P>0.05).The incidence of hand-foot syndrome in the maintenance chemotherapy group was higher than that in the control group,the difference was statistically significant (P<0.05).Conclusion In patients with stage Ⅲcervical cancer,maintenance therapy with Tegafur combined with Apatinib is effective,beneficial to improve quality of life and prolong survival time without increasing serious adverse reactions.

Key words： Stage Ⅲcervical cancer Tegafur Apatinib Maintenance treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Chen
	WANG Haoyuan
	LIANG Meichang

Cite this article:

CHEN Chen,WANG Haoyuan,LIANG Meichang. Clinical effect of Tegafur combined with Apatinib in the maintenance therapy of stage Ⅲcervical cancer[J]. 中国当代医药, 2022, 29(14): 93-95-103.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I14/93

[1]	高子轩，尚雪，郑敏慧.新辅助化疗不同给药方式治疗晚期宫颈癌的疗效及其机制[J].医学临床研究，2019，36（7）：1332-1334.
[2]	李锦梧，胡珊，刘雁云，等.替吉奥、顺铂联合多西他赛协同治疗宫颈癌的临床效果[J].中国医药导报，2020，17（14）：94-97，117.
[3]	彭文盈，梁实，赵玉梅.多西他赛联合替吉奥胶囊对中晚期宫颈癌患者血清肿瘤标记物及免疫水平的影响[J].中国计划生育学杂志，2018，26（6）：460-464.
[4]	成远，华海清，耿海云，等.阿帕替尼为主的方案多线治疗晚期妇科恶性肿瘤的临床观察[J].现代肿瘤医学，2018，26（14）：2266-2271.
[5]	卢丽为，蓝关翠，朱晓华，等.苦参碱注射液对宫颈癌患者新辅助化疗后血清肿瘤标志物水平的影响[J].中国慢性病预防与控制，2018，26（6）：444-446.
[6]	杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4（2）：85-90.
[7]	付玉，齐亮，严丽梅.阿帕替尼联合放化疗治疗复发伴转移宫颈癌的近期疗效及预后影响因素[J].中国临床研究，2020，33（10）：1396-1399.
[8]	李杏婵，何雅婷，赵愚.高危型HPV 感染与宫颈癌前病变、宫颈癌的关系分析[J].中国医药科学，2020，10（16）：71-73.
[9]	赵冬梅.局部晚期宫颈癌患者应用新辅助化疗结合放疗或单纯放疗治疗的临床效果观察[J].中国地方病防治杂志，2018，33（2）：202-204.
[10]	修雨婷，孟凡旭，欧健，等.211 例宫颈癌根治性放疗的预后分析[J].中华放射医学与防护杂志，2019，39（10）：762-767.
[11]	陆绍华，章秀梅，陈寅，等.康艾注射液和替吉奥胶囊联合调强放疗治疗晚期宫颈癌患者的临床观察[J].中国药师，2019，22（6）：1093-1095.
[12]	杨慧春，陈彬彬，宋宝萍，等.术前新辅助化疗治疗局部晚期宫颈癌的临床价值[J].中国妇幼健康研究，2018，29（9）：1189-1193.
[13]	刘莹，张红平，杨宏英.新辅助化疗在局部晚期宫颈癌患者中的应用价值[J].山东医药，2018，58（18）：74-77.
[14]	陈程，马建华，尚玉萍，等.宫颈癌二线治疗失败后甲磺酸阿帕替尼临床应用观察[J].中华肿瘤防治杂志，2019，26（14）：1041-1043，1051.
[15]	崔大伟，季丽梅，胡旻，等.阿帕替尼在巨块型宫颈癌新辅助化疗中的临床研究[J].中国现代应用药学，2019，36（12）：1553-1555.
[16]	左权，向志碧.阿帕替尼在恶性肿瘤治疗中的应用研究进展[J].中国当代医药，2020，27（3）：17-20.
[17]	冯帅，尹月菊，李志强，等.甲磺酸阿帕替尼联合化疗治疗宫颈癌肺转移患者的疗效评估[J].现代妇产科进展，2020，29（10）：760-763.